Identification of PDZD11 as a Potential Biomarker Associated with Immune Infiltration for Diagnosis and Prognosis in Epithelial Ovarian Cancer

Xiaoqi Chen, Zhuang Li, Yanying Feng, Zhijun Yang, Bingbing Zhao

1Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, People’s Republic of China; 2Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education, Nanning, Guangxi, 530021, People’s Republic of China; 3Department of Cardiopulmonary Center, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Bingbing Zhao; Zhijun Yang, Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital, No. 71 Hedi Road, Nanning, Guangxi, 530021, People’s Republic of China, Email zhaobingbing@gxmu.edu.cn; yzj7528@126.com

Purpose: Evidence has indicated that PDZD11 is involved in regulating adherens junction. However, the distinct effect of its aberrant expression on epithelial ovarian cancer (EOC) awaits clarification.

Methods: In this study, public databases (Gene Expression Omnibus, The Cancer Genome Atlas, and The Genotype-Tissue Expression), online analysis tools (Kaplan-Meier plotter and TIMER), and data analysis methods (Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and the CIBERSORT algorithm) were fully utilized to analyze the differential expression, diagnostic efficiency, prognostic significance, potential function, and correlation with immune infiltration of PDZD11. The differential expression of PDZD11 was tested by immunohistochemistry in EOC tissues (78 cases) and control tissues (37 cases).

Results: Our results indicate that PDZD11 was remarkably overexpressed in EOC, which was associated with advanced cancer stages, no lymphatic metastasis status, and poor prognosis. Moreover, PDZD11 played a role in cell adhesion, cell proliferation, and immune responses. Also, PDZD11 was significantly related to the abundances of infiltrating immune cells in EOC, including neutrophils, macrophages, dendritic cells, CD8+ T cells, and CD4+ T cells, and its expression was positively co-expressed with well-known immune checkpoints, including TIGIT, TIM3, LAG3, CTLA4, and PD-1.

Conclusion: These results suggest that PDZD11 could be a potential diagnostic and prognostic biomarker associated with immune infiltration in EOC, and our findings might help elucidate the function of PDZD11 in carcinogenesis.

Keywords: PDZD11, epithelial ovarian cancer, prognostic biomarker, immune infiltration, immune checkpoint

Introduction

Epithelial ovarian cancer (EOC) is ranked as one of the most lethal gynecological cancers. Type II EOCs, including high-grade serous ovarian cancer, have a particularly poor prognosis because they are characterized by high-frequency oncogene mutations, including P53 and BRCA, and are more likely to invade and spread.1 In 2020, 313,959 women were diagnosed with EOC worldwide, and 207,252 women died from it; the incidence and age-world-standardized mortality rate of this disease is 6.6 and 4.2 per 100,000, respectively.2 The tumor spreads easily to the pelvic and abdominal cavities and about 75% of cases are diagnosed at an advanced stage.3 BRCA1 and BRCA2 mutations carriers account for about 6–15% of EOC cases, and these cases present a better response to platinum-based chemotherapy and poly ADP-ribose polymerase (PARP) inhibitors, which has improved the survival rate of EOC patients to some extent.4 However, the overall treatment of advanced EOC remains challenging. Frustratingly, early detection is difficult for EOC due to its asymptomatic nature in the early stages. Although the number of asymptomatic ovarian masses found in late
childbearing women has increased with the use of prenatal ultrasound, early EOC detection rate has not been greatly improved. At present, CA125 and HE4 are the only approved biomarkers for EOC. Some evidence suggests that various biomarkers combined with patient characteristics into a multivariate index, such as OVA1, ROMA, and Overa, could increase the detection rate of early EOC. However, they are not sufficient for EOC early diagnosis. Searching for effective biomarkers to detect and diagnose this cancer and to predict the outcomes of patients has thus become imperative.

PDZ Domain Containing 11 (PDZD11), a small protein widely expressed in the body, is mainly comprised of a single PDZ domain. PDZD11 has often been reported to be associated with the adherens junction (AJ) of epithelial cells. AJ is a component of cell–cell junctions and is essential for maintaining cell–cell adhesion. PDZD11 binds nectins to the cadherin-and cytoskeleton-related protein complex by interacting with PLEKHA7 to stabilize the nexins at AJs and promotes efficient early assembly of junctions. Some aberrantly expressed AJ-related molecules have been shown to be potential prognostic biomarkers or therapeutic targets for certain cancers. Regrettably, the role of PDZD11 as a cell adhesion-related protein in tumors has rarely been studied. The aim of this study was to provide new insights into the underlying regulatory effects of PDZD11 on carcinogenesis and immune infiltration as well as its application as a diagnostic and prognostic biomarker for EOC.
Methods

Data Mining and Processing
The mRNA expression data (Table S1) in this study were accessed from Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA) and The Genotype-Tissue Expression (GTEx) public resources. In the GEO database, the keywords “ovarian cancer” and “carcinoma of ovary” were entered to retrieve the transcript data of EOC and nontumor control tissues. Unstandardized mRNA expression values were normalized by log₂(x+0.001) formula. To obtain the data of the TCGA-GTEX cohort, TCGA and GTEx data in FPKM format were downloaded through the UCSC Xena database, and mRNA expression values from the two datasets were normalized by log₂(x+0.001) formula and converted into the TPM format; then, the expression information of normal ovarian tissues was extracted from GTEx data and integrated into the mRNA expression matrix of EOC tissues from TCGA. R package impute (http://bioconductor.org/packages/impute/) was used to process missing values in all mRNA expression matrix. The clinical data of patients with EOC were also downloaded from the UCSC Xena platform.

Analysis of the Protein Expression Level of PDZD11 in EOC
After obtaining informed written consent from each patient, we collected 37 cases of normal ovarian tissues, 38 cases of primary EOC samples, and 40 cases of metastatic EOC specimens (Table 1) from Guangxi Medical University Cancer Hospital from January 2023 to November 2023. Normal ovarian tissues were obtained from non-malignant cases, and all were pathologically diagnosed as non-diseased ovarian tissues. All EOC tissues were pathologically diagnosed as serous histological type. The research was conducted in accordance with the Declaration of Helsinki, and approved by the Medical Ethics Committee of Guangxi Medical University Cancer Hospital (protocol code: LW2023003, January 5, 2023). After being deparaffinized, rehydrated and repaired, tissue sections were incubated with the primary antibody against PDZD11 (1/850 dilution, PHW3840, Abmart, Shanghai, China), and combined with goat anti-rabbit antibody (MaxVision TM HRP-Polymer anti-Rabbit IHC Kit, MAIXIN BIOTECH, Fuzhou, China). Finally, tissue slices were stained using DAB and counterstained with hematoxylin. The staining intensity (SI) and the proportion of positive cells (PP) were evaluated by two pathologists in 10 randomly selected fields under a microscope. Immunoreactive score (IRS) = SI × PP. SI was assigned as: 0 = negative, 1 = weak, 2 = moderate, or 3 = strong. PP was defined as 0 = 0%, 1 = 0–10%, 2 = 11–50%, 3 = 51–80%, and 4 = 81–100%.

Diagnostic Value Analysis of PDZD11 in EOC
Receiver operating characteristic (ROC) curves were plotted using GraphPad Prism 9 software, and the area under the curve (AUC) was calculated to estimate the discrimination capacity of PDZD11 for EOC. To achieve higher quality of diagnostic evaluation, the diagnostic information of PDZD11 from independent ROC curves was integrated into the summary ROC (SROC) curve using Stata 15 software (https://stata.com/).

Prognostic Potential Analysis of PDZD11 in EOC Patients
The ovarian cancer module of Kaplan-Meier (KM) plotter was utilized to examine the correlation between PDZD11 mRNA levels and EOC patients’ survival. Based on the auto select best cutoff value on the website, EOC cases were divided into PDZD11 high-mRNA level and low-mRNA level groups, and the OS, PFS and PPS of the two groups were compared. The prognostic analysis of PDZD11 in EOC patients stratified by stage, histology, or therapeutic method was also performed.

GO and KEGG Enrichment
The biological process (BP), cellular component (CC), and molecular function (MF) terms of PDZD11 were identified by Gene Ontology (GO) analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment was performed to reveal the PDZD11-associated pathways. Briefly, based on TCGA-GTEX data, differentially expressed genes (DEGs) in EOC were verified with R package limma (http://bioconductor.org/packages/limma/), thresholds: | log₂-fold change | > 1, adjusted p values < 0.05); PDZD11 co-expressed genes were screened out through R programming (https://r-project.org/).
<table>
<thead>
<tr>
<th>characteristics</th>
<th>TCGA (n = 374)</th>
<th>PDZD11 mRNA expression</th>
<th>p-value</th>
<th>Local primary tissue cases (n = 38)</th>
<th>PDZD11 IRS</th>
<th>p-value</th>
<th>Local metastatic tissue cases (n = 40)</th>
<th>PDZD11 IRS</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Median (min-max) or mean ± SE</td>
<td></td>
<td>Median (min-max)</td>
<td>Median (min-max)</td>
<td></td>
<td>Median (min-max)</td>
<td>Median (min-max)</td>
<td></td>
</tr>
<tr>
<td>Age*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.0078</td>
</tr>
<tr>
<td>≤ Median age</td>
<td>196</td>
<td>5.55 (3.66,6.39)</td>
<td>0.0078</td>
<td>20</td>
<td>6.00 (1.00,9.00)</td>
<td></td>
<td>21</td>
<td>9.00 (1.00,9.00)</td>
<td></td>
</tr>
<tr>
<td>&gt; Median age</td>
<td>178</td>
<td>5.44 (3.81,6.91)</td>
<td>0.4229</td>
<td>18</td>
<td>9.00 (2.00,12.00)</td>
<td>0.8848</td>
<td>19</td>
<td>2.00 (0.00,9.00)</td>
<td></td>
</tr>
<tr>
<td>Grade</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G1/G2</td>
<td>43</td>
<td>5.57 (3.73,6.89)</td>
<td>0.0133</td>
<td>3</td>
<td>9.00 (2.00,9.00)</td>
<td></td>
<td>0</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>G3</td>
<td>320</td>
<td>5.51 (3.66,6.91)</td>
<td></td>
<td>35</td>
<td>6.00 (1.00,12.00)</td>
<td></td>
<td>40</td>
<td>6.00 (0.00,9.00)</td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>11</td>
<td>-</td>
<td></td>
<td></td>
<td>-</td>
<td></td>
<td></td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I/II</td>
<td>22</td>
<td>5.16 ± 0.78</td>
<td></td>
<td>2</td>
<td>7.50 (6.00,9.00)</td>
<td></td>
<td>2</td>
<td>1.00 (0.00,2.00)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>292</td>
<td>5.47 ± 0.49</td>
<td></td>
<td>28</td>
<td>6.00 (1.00,12.00)</td>
<td></td>
<td>22</td>
<td>5.00 (0.00,9.00)</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>57</td>
<td>5.52 ± 0.48</td>
<td>0.9645</td>
<td>8</td>
<td>9.00 (2.00,9.00)</td>
<td></td>
<td>16</td>
<td>6.00 (0.00,9.00)</td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>3</td>
<td>-</td>
<td></td>
<td></td>
<td>-</td>
<td></td>
<td></td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Histological types</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serous</td>
<td>374</td>
<td>5.50 (3.66,6.91)</td>
<td></td>
<td>38</td>
<td>6.00 (1.00,12.00)</td>
<td></td>
<td>40</td>
<td>6.00 (0.00,9.00)</td>
<td></td>
</tr>
<tr>
<td>Endometrioid</td>
<td>0</td>
<td>-</td>
<td></td>
<td>0</td>
<td>0</td>
<td></td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Mucinous</td>
<td>0</td>
<td>-</td>
<td></td>
<td>0</td>
<td>0</td>
<td></td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Lymphatic metastasis</td>
<td></td>
<td></td>
<td>0.9645</td>
<td>0</td>
<td>0</td>
<td></td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>100</td>
<td>5.50 (4.23,6.89)</td>
<td>0.9645</td>
<td>21</td>
<td>6.00 (1.00,9.00)</td>
<td>0.0288</td>
<td>20</td>
<td>6.00 (0.00,9.00)</td>
<td>0.7664</td>
</tr>
<tr>
<td>No</td>
<td>47</td>
<td>5.46 (3.66,6.68)</td>
<td></td>
<td>17</td>
<td>9.00 (4.00,12.00)</td>
<td></td>
<td>20</td>
<td>6.00 (0.00,9.00)</td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>227</td>
<td>-</td>
<td>0.2364</td>
<td></td>
<td>-</td>
<td></td>
<td></td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>324</td>
<td>5.51 (3.66,6.91)</td>
<td></td>
<td>0</td>
<td>0</td>
<td></td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>25</td>
<td>5.42 (3.81,6.84)</td>
<td></td>
<td>0</td>
<td>0</td>
<td></td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>11</td>
<td>5.47 (4.79,6.68)</td>
<td></td>
<td>38</td>
<td>6.00 (1.00,12.00)</td>
<td></td>
<td>40</td>
<td>6.00 (0.00,9.00)</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>3</td>
<td>5.15 (4.57,5.58)</td>
<td></td>
<td></td>
<td>-</td>
<td></td>
<td></td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>11</td>
<td>-</td>
<td></td>
<td></td>
<td>-</td>
<td></td>
<td></td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

Note: *Median age of TCGA cases is 59; of local primary tissues cases is 55; and of local metastatic tissues cases is 53.
Abbreviation: IRS, immunoreactive score.
thresholds: \(| r | > 0.3 \) and \( p < 0.05 \). Eventually, the intersection genes of the DEGs and the PDZD11 co-expressed genes were brought into GO and KEGG analyses through the R package cluster Profiler (http://bioconductor.org/packages/clusterProfiler/).

**Correlation Analysis Between PDZD11 mRNA Levels and Immune Infiltration in EOC**

The TIMER database\(^{19}\) was used to assess the correlations between PDZD11 expression and the infiltration abundances of six types of infiltrating immune cells in EOC. The infiltration proportions of 22 types immune cell subsets in the 379 EOC samples from TCGA were further calculated by CIBERSORT\(^{20}\) (https://cibersortx.stanford.edu/) tool. Based on the median expression value of PDZD11, the 379 EOC samples were grouped into high-mRNA level and low-mRNA level patient sets, and the infiltration levels of 22 types of immune cells in the two sets were compared. Associations of PDZD11 mRNA levels and immune checkpoints were assessed using the correlation module of TIMER.

**Statistical Analysis**

PDZD11 expression in different groups was compared using Student’s t-test, Mann–Whitney test, one-way ANOVA test, Kruskal–Wallis test, or chi-square test. The standardized mean difference (SMD) of PDZD11 expression was calculated by the R package Meta (https://github.com/guido-s/meta). Survival analysis of EOC patients was performed using KM analysis and the log rank test. Infiltration fractions of 22 types of immune cells between PDZD11 high-mRNA level and low-mRNA level patient sets were compared using the Mann–Whitney test. Genes co-expressed with PDZD11 were screened out based on Pearson’s correlation. Moreover, the correlation analyses between PDZD11 expression and immune checkpoints were performed using Pearson’s correlation or Spearman correlation. Statistical analyses were performed by SPSS23.0 and GraphPad Prism 9 and partially visualized by Sangerbox 3.0 tool.\(^{21}\) \( P < 0.05 \) were considered statistically significant.

**Results**

**Transcription Expression of PDZD11 in EOC and Other Cancers**

We assessed PDZD11 mRNA levels in 11 different GEO datasets (Table S1), of which six (GSE10971, GSE119054, GSE14407, GSE15578, GSE27651, and GSE38666) showed that EOC tissues had an enhanced level of PDZD11 expression compared with normal tissues (Figure 1A–D, F and G), whereas no significant differences in PDZD11 expression between the two types of tissues were observed in another five GEO datasets (Figure 1E and 1H-K). Additionally, upregulation of PDZD11 expression in EOC was further confirmed in the TCGA-GTEX ovarian cohort (Figure 1L). Furthermore, the SMD was calculated to comprehensively analyze the expression of PDZD11. The random-effect model was selected in this study because the heterogeneity was obvious (\( I^2 > 50\% \)). SMD > 0 suggested that PDZD11 was generally upregulated in EOC tissues compared with the control group (Figure 1M).

**The Protein Expression Level of PDZD11 in EOC**

Upregulated PDZD11 protein expression was observed in 78 EOC cases (38 primary tissues and 40 metastatic tissues) with histological type of serous, compared with 37 normal ovarian samples (Figure 1N). Metastatic EOC tissues had a slightly lower proportion of high PDZD11 protein expression level than primary EOC tissues (Figure 1O).

**PDZD11 Expression in EOC Patients with Different Clinicopathological Characteristics**

We analyzed the correlations between PDZD11 expression and clinicopathological parameters of EOC patients, based on clinical information of 374 EOC patients from the TCGA open resource and 78 local EOC cases. Our results suggested that PDZD11 mRNA expression was remarkably elevated in EOC patients with advanced cancer stages (Table 1). Interestingly, in the 38 cases of primary EOC tissues collected in this study, the PDZD11 protein was downregulated in
Figure 1 Expression levels of PDZD11 in epithelial ovarian cancer (EOC). (A-K) Comparison of PDZD11 transcriptional expression levels between EOC tissues and normal controls in 11 different GEO datasets. (L) PDZD11 was overexpressed in EOC tissues in the TCGA-GTEx cohort. (M) Standardized mean difference of PDZD11 expression level based on all datasets included in this study. (N) IHC result of PDZD11 expression in noncancerous ovarian tissues (n = 37), primary EOC tissues (n = 38), and metastatic EOC tissues (n = 40). (O) Distribution ratio of PDZD11 protein expression level in primary EOC tissues and metastatic EOC tissues. (P) The ability of PDZD11 protein to distinguish cancerous from non-cancerous tissues analyzed in local 78 EOC tissues and 37 normal ovarian samples. -ns, P > 0.05; *, P < 0.05; **, P < 0.01; ****, P < 0.0001.
EOC patients with lymph node metastasis (Table 1). Moreover, in local metastatic tissue cases, PDZD11 level was strongly related to younger age (Table 1).

### Diagnostic Value of PDZD11 in EOC

ROC curves and a SROC curve were drawn to assess the ability of PDZD11 to distinguish EOC from normal tissues. According to AUC, moderate diagnostic accuracy (AUC = 0.85 and \(p < 0.0001\)) of PDZD11 protein was observed in local EOC cases (Figure 1P); high diagnostic accuracy (AUC > 0.9 and \(p < 0.05\)) of PDZD11 mRNA was observed in data sets GSE119054 (Figure 2B), GSE15578 (Figure 2D), and TCGA-GTEx (Figure 2L); moderate diagnostic accuracy...
(AUC = 0.7–0.9 and \( p < 0.05 \)) of PDZD11 mRNA was observed in data sets GSE10971 (Figure 2A), GSE14407 (Figure 2C), GSE27651 (Figure 2F), and GSE38666 (Figure 2G), while PDZD11 mRNA showed poor diagnostic accuracy (AUC = 0.5–0.7 or \( p > 0.05 \)) in datasets GSE18520 (Figure 2E), GSE54388 (Figure 2H), GSE66957 (Figure 2I), GSE69428 (Figure 2J), and GSE69429 (Figure 2K), respectively. More importantly, the SROC curve indicated that PDZD11 mRNA has high comprehensive diagnostic accuracy with AUC = 0.94 (\( p < 0.0001 \)) in EOC (Figure 2M).

### Prognostic Value of PDZD11 in EOC Patients

To determine the prognostic potential of PDZD11, the correlation between PDZD11 mRNA levels and the outcomes of EOC patients was investigated using the KM plotter. Elevated PDZD11 expression was related to worse OS and PFS in EOC cases in the KM database (Figure 3A). Also, stratified survival analysis suggested that a higher PDZD11 mRNA level was markedly linked with inferior OS in EOC patients at advanced cancer stages (stages 3 or 4) or in EOC cases with the cancer histological type of endometrioid carcinoma (Figure 3B and 3C). Furthermore, increased PDZD11 mRNA level was correlated with poor PFS in EOC cases with advanced cancer stages or in EOC patients with the cancer histological types of serous or endometrioid carcinoma (Figure 3B and 3C). Interestingly, the PDZD11 expression levels could also predict the prognoses of EOC patients receiving different treatments. Patients with a higher mRNA level of PDZD11 had worse OS after suboptimal debulk (Figure 3D). Similarly, patients with lower expression of PDZD11 had better prognosis after chemotherapy containing taxol, platinum, or taxol combined with platinum (Figure 3D).

### GO and KEGG Analyses of PDZD11 in EOC

To investigate the role of PDZD11 in EOC, we identified 930 overexpressed genes that were positively correlated with PDZD11 and 1,148 downregulated genes that were negatively correlated with PDZD11 in EOC from TCGA database for GO and KEGG analyses, respectively. The top 60 PDZD11-associated genes in EOC are shown in the heatmap (Figure 4A). For genes positively correlated with PDZD11 expression, the top five BP terms of enrichment were nuclear division, humoral immune response, chromosome segregation, mitotic nuclear division, and immunoglobulin-mediated immune response; the top five CC terms enriched were cell–cell junction, apical plasma membrane, apical junction complex, tight junction, and bicuscular tight junction; the top five MF terms enriched were cadherin binding, antigen binding, cell adhesion mediator activity, cell–cell adhesion mediator activity, and virus receptor activity (Figure 4B). KEGG enrichment analysis indicated that PDZD11 was correlated with cell adhesion molecules and the cell cycle (Figure 4C). Notably, PDZD11 was also associated with immune responses, such as human papillomavirus infection, Epstein–Barr virus infection, human T-cell leukemia virus 1 infection, Staphylococcus aureus infection, phagosome, pathogenic Escherichia coli infection, leukocyte transendothelial migration, antigen processing and presentation, Th1 and Th2 cell differentiation, intestinal immune network for IgA production, and autoimmune thyroid disease (Figure 4C).

For genes negatively correlated with PDZD11 expression, the main enriched BP, CC, and MF are shown in the bubble diagram (Figure 4D). KEGG pathways enriched of these genes included the Ras signaling pathway, the Rap1 signaling pathway, choline metabolism in cancer, and platinum drug resistance (Figure 4E). Our results suggest that PDZD11 may affect cell adhesion, cell proliferation, immune responses, and certain tumor-related signaling pathways.

### Association Between PDZD11 mRNA Levels and Immune Infiltration in EOC

Studies have found that tumor-infiltrating immune cells were connected with cancer development and prognoses in EOC patients.\(^{22,23}\) Interestingly, the enrichment analyses described above revealed that PDZD11 was associated with immune responses in EOC. Hence, we used the TIMER online tool to assess the associations between PDZD11 expression and the infiltration proportions of six common types of immune cells in EOC. PDZD11 displayed positive correlations with the infiltration abundances of neutrophils, macrophages, dendritic cells, CD8+ T cells, and CD4+ T cells (Figure 5A). To further study the associations between PDZD11 mRNA levels and infiltration abundances of more immune cell subsets, we used the analytical tool CIBERSORT to compute the infiltrating proportions of 22 types of immune cells in 379 EOC samples from the TCGA database. High infiltrating proportions of T cells and macrophages in EOC were observed in the heat map (Figure 5C). Subsequently, infiltration levels of the 22 types of immune cells in the PDZD11 high-mRNA level
and low-mRNA level samples were compared. The infiltration levels of CD8+ T cells, follicular helper T cells, Gamma Delta T cells, and M1 macrophages in the PDZD11 high-expression samples were elevated compared with the low-expression samples, while resting natural killer cells and M0 macrophages were the opposite (Figure 5B). However, no obvious differences were found in the infiltration fractions of other immune cells between the two groups (Figure 5B).

Figure 3 Prognostic potential of PDZD11 in EOC analyzed in the Kaplan-Meier (KM) plotter. (A) KM estimates of OS, PFS, and PPS in EOC patients with different PDZD11 mRNA levels. Prognostic value analysis of PDZD11 stratified by (B) cancer stages, (C) histological types, and (D) therapeutic methods.

Abbreviations: HR, hazard ratio; CI, confidence interval.
Figure 4 Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses for PDZD11 and its co-expressed genes in EOC. (A) Heatmap showing the top 60 PDZD11 co-expressed genes in EOC in the TCGA data. Bubble chart exhibiting the top 10 terms of the biological process (BP), cellular component (CC), and molecular function (MF) enriched of PDZD11 (B) positively and (D) negatively co-expressed genes in EOC, respectively. (C) Bubble chart showing the top 30 signaling pathways enriched of PDZD11 positively co-expressed genes in EOC. (E) Bubble chart showing the top seven signaling pathways of enrichment of PDZD11 negatively co-expressed genes in EOC.
Figure 5 Immune landscape of PDZD11 in EOC analyzed in TIMER and TCGA database. (A) Associations between PDZD11 expression and infiltration proportions of six common types of immune cells in EOC in TIMER. (B) Comparisons of the infiltration levels of diverse immune cells in PDZD11 high-mRNA level and low-mRNA level EOC samples from the TCGA database. (C) Infiltration proportions of the 22 types of immune cells in EOC in TCGA, calculated by the CIBERSORT algorithm. (D) The expression of immune checkpoints in the PDZD11 high-mRNA level group compared with the low-mRNA level group based on TCGA data. (E) Expression correlations between PDZD11 and immune checkpoints in EOC analyzed in TIMER. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Correlations Between PDZD11 and Expression of Immune Checkpoints

Immune checkpoint blockade (ICB) therapy is one of the methods of immunotherapy against tumors and has been approved for the treatment of melanoma,\(^4\) lung cancer,\(^5\) renal cell carcinoma\(^6\) and other cancers. Although immune checkpoint inhibitors alone are ineffective for EOC patients, they have been shown to be effective in combination with chemotherapy, targeted therapy, and PARP inhibitors.\(^7,8\) It is shown that PARP inhibitors may enhance the efficacy of immune checkpoint inhibitors (ICIs) through multiple potential immune-enhancing mechanisms. Tumors with homologous recombination deficiency have higher mutation, which enhances neoantigen formation, increasing stronger immune response against cancer.\(^9\) Also, evidence has indicated that PARP inhibitors facilitate interferon type I response by activating the cyclic GMP-AMP synthase-STING pathway, enhancing antigen presentation.\(^10\) Moreover, PARP inhibitors have been shown to upregulate PD-L1 expression by inactivating glycogen synthase kinase 3β, weakening tumor immune response,\(^9\) and this could be rescued by PD-L1 blockade.\(^9\) We thus performed the correlation analyses between PDZD11 mRNA levels and well-known immune checkpoints, including TIGIT, HAVCR2 (TIM3), LAG3, CTLA4, PDCD-1 (PD-1), and CD274(PD-L1). The expressions of TIGIT, TIM3, LAG3, CTLA4, and PD-1 in the PDZD11 high-expression samples were higher than in the PDZD11 low-expression samples based on TCGA data, while PDZD11 was not significantly correlated with PD-L1 expression levels (Figure 5D). We also calculated the correlation coefficients between PDZD11 expression and the above six immune checkpoints in EOC using the correlation module of TIMER. PDZD11 was positively correlated with TIGIT, TIM3, LAG3, CTLA4, and PD-1, but not with PD-L1 (Figure 5E).

Discussion

Growing studies have found that PDZD11 is a gene related to AJs.\(^8,11,31,32\) However, the potential effect of its abnormal expression on tumorigenesis has rarely been investigated. Our comprehensive analysis indicated that PDZD11 expression was strongly increased in EOC tissues compared with control samples (Figure 1). PDZD11 were closely related to cancer stages and no lymph node metastasis status (Table 1), which demonstrated that PDZD11 may be associated with tumor development of EOC. Subsequently, the ROC and SROC curves showed that PDZD11 had a certain ability to distinguish EOC tissues from normal tissues (Figure 1P and 2). The KM plotter results demonstrated that the PDZD11 expression levels could predict the survival of EOC patients. EOC patients with increased PDZD11 expression had short OS and PFS time (Figure 3A). Also, for EOC patients at advanced cancer stages or with the cancer histological type of endometrioid carcinoma, elevated PDZD11 expression was significantly linked with poor OS (Figure 3B and 3C). Furthermore, for EOC patients at advanced cancer stages or with the histological types of serous or endometrioid carcinoma, higher PDZD11 expression was correlated with worse PFS (Figure 3B and 3C). A similar prognostic significance of PDZD11 was observed in EOC patients receiving different treatments. Patients with lower PDZD11 mRNA expression level have a better prognosis after suboptimal debulk or chemotherapy containing taxol, platinum, or taxol combined with platinum (Figure 3D). Although this work discovered that PDZD11 expression was elevated in EOC and exhibited certain diagnostic and prognostic potential, the clinical availability of these results needs to be validated in multi-level, multi-sample, and multi-center studies. More importantly, the difference in serum PDZD11 expression levels between EOC patients and healthy individuals also remains to be validated to test whether it is convenient for clinical detection.

EOC remains refractory due to its characteristics of extensive pelvic and abdominal metastases. Studies have reported that EMT is a crucial process in cancer metastasis.\(^33,34\) Epithelial cancer cells lose their typical cell–cell junctions, as well as apical-basal polarity, and gain some characteristics of mesenchymal cells to facilitate migration and to achieve the invasion-metastasis cascade.\(^35\) Our results of GO analysis indicated that PDZD11-co-expressed genes were mainly enriched in BP terms of cell–cell junction organization and in CC terms of cell–cell junction, apical junction complex, tight junction, and bicellular tight junction and involved in cell–cell adhesion-related MFs such as cadherin binding, cell adhesion mediator activity, and cell–cell adhesion mediator activity (Figure 4B). Moreover, PDZD11 was shown to be involved in the KEGG pathways of cell adhesion molecules and tight junctions (Figure 4C). More importantly, our IHC validation results suggested that metastatic EOC tissues had a slightly higher ratio of low PDZD11 protein expression.
levels than primary EOC tissues (Figure 1O), and the PDZD11 protein was downregulated in EOC cases with lymph node metastasis (Table 1). Based on the results above, we speculate that, like other AJ-related proteins, such as E-cadherin, the loss of PDZD11 may induce EMT. However, in this study, PDZD11 expression was elevated in EOC tissues, and GO and KEGG analysis indicated that it was associated with nuclear division, chromosome segregation, mitotic nuclear division, and the cell cycle pathway, which illustrated that PDZD11 may promote the cell proliferation of EOC (Figure 4C). PDZD11, like E-cadherin,36,37 may have a dual role in EOC. It may contribute to the survival and proliferation of cancer cells, and its decreased expression may also promote metastasis.

Recruited by tumor microenvironment (TME), infiltrating immune cells participate in tumor-associated immune responses or tumor escape. Growing research has found that immune cells in TME, including CD8+ cytotoxic T lymphocytes, CD4+ T cells, natural killer cells, dendritic cells, macrophages, B cells, mast cells, and neutrophils, show certain prognostic significance in human cancer.38 Among them, TAMs,39 regulatory T cells,40 and neutrophils41 play a crucial role in the tumor antigen presentation process blocking and immune surveillance evasion, thereby promoting tumor development, while dendritic cells41 and CD8+ cytotoxic T lymphocytes42 play a significant role in killing cancer cells. Effects of infiltrating immune cells on patients’ outcomes have been reported in EOC: in patients with high-grade serous EOC, a higher infiltration of CD208+ dendritic cells was found to be associated with better OS.43 Whereas high level of TAMs correlated with adverse prognosis in EOC.44 Interestingly, KEGG analysis in this research revealed that PDZD11 was associated with human papillomavirus infection, human T-cell leukemia virus 1 infection, Staphylococcus aureus infection, pathogenic Escherichia coli infection, leukocyte transendothelial migration, antigen processing and presentation, Th1 and Th2 cell differentiation, and other immune responses (Figure 4C). Consistently, PDZD11 mRNA expression was remarkably and positively linked with the infiltration proportions of neutrophils, macrophages, dendritic cells, CD8+ T cells, and CD4+ T cells in EOC (Figure 5A).

Immunotherapy, as a cutting-edge therapy, has been proven to improve the survival of many cancer patients.45 Immunotherapy mainly includes adoptive T-cell therapy, tumor vaccines, and ICB therapy.27 The generation of immune checkpoints is a way for the body to establish immune tolerance and prevent autoimmunity, and tumors can stimulate the expression of immune checkpoints to achieve immune evasion. We assessed the correlations between PDZD11 expression and well-known immune checkpoints in EOC. The expression of TIGIT, TIM3, LAG3, CTLA4, and PD-1 in the PDZD11 high-mRNA level group was higher than in the PDZD11 low-mRNA level group (Figure 5D). In addition, PDZD11 was positively correlated with TIGIT, TIM3, LAG3, CTLA4, and PD-1 (Figure 5E). Our findings suggest that PDZD11 is a biomarker associated with immune infiltration and expression of immune checkpoints in EOC.

However, our research has some limitations. First of all, our conclusions are mostly based on the results of bioinformatics analysis. Although we have verified the differential expression of PDZD11 protein in local EOC cases (37 cases of normal ovarian tissues, 38 cases of primary EOC samples, and 40 cases of metastatic EOC specimens), and analyzed its correlations with patient clinicopathological parameters, validations from multi-level, multi-sample, and multi-center studies are needed. Secondly, the mechanisms of PDZD11 in tumor-related immune responses in EOC need to be further explored in experimental studies.

Conclusions

In summary, PDZD11 was upregulated in EOC tissues and showed certain diagnostic ability in EOC. Increased PDZD11 expression was related to adverse prognosis of EOC patients. PDZD11 was related to cell adhesion, decreased in EOC patients with lymphatic metastasis, and involved in the process of cell proliferation. PDZD11 was significantly linked with immune infiltration in EOC and positively correlated with the expression of immune checkpoints, including TIGIT, TIM3, LAG3, CTLA4, and PD-1, suggesting that it may play a certain role in immune responses in EOC. This study concludes that PDZD11 is a potential diagnostic and prognostic biomarker of EOC.

Abbreviations

AJ, Adherens junction; AUC, Area under the curve; BP, Biological process; CC, Cellular component; CI, Confidence interval; CJs, Cell-cell junctions; DEGs, Differentially expressed genes; EMT, Epithelial mesenchymal transition; EOC,
Epithelial ovarian cancer; FPKM, Fragments per kilobase of exon model per million reads mapped fragments; GEO, Gene Expression Omnibus; GEPIA, Gene Expression Profiling Interactive Analysis; GO, Gene Ontology; GTEx, The Genotype-Tissue Expression; ICIs, Immune Checkpoint Inhibitors; IHC, Immunohistochemical; IRS, Immunoreactive score; KEGG, Kyoto Encyclopedia of Genes and Genomes; KM plotter, Kaplan-Meier plotter; MF, Molecular function; OS, Overall Survival; PFS, Progression Free Survival; PP, Proportion of positive cells; PPS, Post progression survival; ROC, Receiver operating characteristic; SI, Staining intensity; SMD, Standardized mean difference; sROC, Summary receiver operating characteristic; TAMs, Tumor-associated macrophages; TCGA, The Cancer Genome Atlas; TME, Tumor microenvironment; UCSC, University of California Santa Cruz.

Data Sharing Statement

Ethics Approval and Informed Consent
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Medical Ethics Committee of Guangxi Medical University Cancer Hospital (protocol code: LW2023003, date: January 5, 2023). Informed consent was obtained from all subjects involved in the study.

Acknowledgments
We appreciate all open databases and online analytic tools used in this study as well as financial support for this work. We are grateful to Figdraw (https://www.figdraw.com) for the graphical material (authorization ID: YIOWY27f24) in the graphical abstract.

Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding
This work was supported by Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education (GKE-zz 202018, GKE-zz 202121), Guangxi medical high-level backbone personnel training “139” Project (No.201414, No.201822), Special Fund of the 17th Guangxi New Century “Ten, Hundred, Thousand” Talent Project (No.2014210), Guangxi Zhuang Autonomous Region Key Clinical Specialty Construction Project (2018-39), and Guangxi Natural Science Foundation (2023GXNSFAA026216, 2023GXNSFBA026101).

Disclosure
The authors declare no conflicts of interest.

References